ADVANCED TARGETED RADIOFLUORESCENCE & THERAPY
Forging our goal of self guided surgeries
Embedded Files
MULTIMODALITY RADIOLIGAND THERANOSTIC NOVEL DRUG FOR DISEASE MANAGEMENT
At Antelope Surgical Solutions, Inc., we are driven by our passion for developing cutting-edge products that will revolutionize the medical biotechnology industry. Since our founding in 2020, we’ve established a GMP manufacturing facility equipped with robotic high-throughput synthesis capabilities and received our first FDA IND clearance for our lead agent. Our innovative multimodal small molecule, designed for diagnostic, radiotherapeutic, and fluorescence-guided surgical applications, is built upon our patent pending, first-of-its-kind chemical syntheses. With a team of experts, we are committed to inspiring and leading with our groundbreaking ideas and expertise.
Streamlining of long-term pipelines in accordance with GMP Standards
REDEFINING THE FIELD OF IMAGE GUIDED SURGERY
TENETS
Definitive in vivo identification of tumors and metastases during surgery
PET, MR, CT, US, and SPECT imaging techniques often lack the resolution needed to accurately define the spatial boundaries of lymph node metastases and positive margins, limiting the crucial information available to surgeons during procedures. Antelope Surgical Solutions has promising preliminary data in fluorescence-guided surgery and is actively working on developing additional imaging agents for future applications to enhance surgical precision. FDA IND cleared Phase I/II begins summer 2025.
GMP Synthesis
Development pipelines for single-modality diagnostic imaging agents typically take 8 to 10 years and cost between $100-200 million. Antelope Surgical's current pipeline includes two imaging agents, with plans to expand and introduce more in the future.
Proprietary Solutions
We aim to have the first multimodality radioligand therapeutic and fluorescent agent approved by the US Food and Drug Administration on the market.
Page updated
Report abuse